4-[6-chloro-3-[(E)-2-(3-dimethylaminomethyl-phenyl)-vinyl]-1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-4-carbonyl]-piperazine-1-carboxylic acid tert-butyl ester | 1426918-27-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 4-[6-chloro-3-[(E)-2-(3-dimethylaminomethyl-phenyl)-vinyl]-1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-4-carbonyl]-piperazine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 4-[6-chloro-3-[(E)-2-[3-[(dimethylamino)methyl]phenyl]ethenyl]-1-(oxan-2-yl)pyrazolo[3,4-b]pyridine-4-carbonyl]piperazine-1-carboxylate
• CAS: 1426918-27-5
• 化学式: C₃₂H₄₁ClN₆O₄
• 分子量: 609.168
• InChiKey: VRTITRQJINOMNG-OUKQBFOZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  43
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  93
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  6-chloro-3-iodo-1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid 在 bis-triphenylphosphine-palladium(II) chloride 、 四丁基溴化铵 、 palladium diacetate 、 碳酸氢钠 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 N,N-二甲基乙酰胺 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 4-[6-chloro-3-[(E)-2-(3-dimethylaminomethyl-phenyl)-vinyl]-1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-4-carbonyl]-piperazine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  [EN] 6-(4-HYDROXY-PHENYL)-3-STYRYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS
  [FR] DÉRIVÉS AMIDES D'ACIDE 6-(4-HYDROXYPHÉNYL)-3-STYRYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIQUE EN TANT QU'INHIBITEURS DE KINASE

  摘要：

  本发明涉及具有以下式I的吡唑并[3,4-b]吡啶化合物，其中R1、R2、R3、R4和R5如下所示。式I的化合物是激酶抑制剂，可用于治疗与糖尿病及糖尿病并发症相关的疾病，例如糖尿病肾病、糖尿病神经病变和糖尿病视网膜病变等。此外，该发明还涉及将式I的化合物用作药物中的活性成分，以及包含它们的药物组合物。

  公开号：

  WO2013037390A1

文献信息

• 6-(4-HYDROXY-PHENYL)-3-STYRYL-1H-PYRAZOLO[3,4-b]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS
  申请人：LOEHN Matthias

  公开号：US20130065894A1

  公开（公告）日：2013-03-14

  The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I, in which R 1 , R 2 , R 3 , R 4 and R 5 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的吡唑啉[3,4-b]吡啶化合物，其中R1、R2、R3、R4和R5如下所示。式I的化合物是激酶抑制剂，可用于治疗与糖尿病及糖尿病并发症相关的疾病，如糖尿病肾病、糖尿病神经病变和糖尿病视网膜病变等。此外，该发明还涉及式I的化合物的用途，特别是作为药物中的活性成分，以及包含它们的药物组合物。
• 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
  申请人：Loehn Matthias

  公开号：US08846712B2

  公开（公告）日：2014-09-30

  The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I, in which R1, R2, R3, R4 and R5 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的吡唑并[3,4-b]吡啶化合物，其中R1、R2、R3、R4和R5如下所示。式I的化合物是激酶抑制剂，并且可用于治疗与糖尿病和糖尿病并发症相关的疾病，例如糖尿病肾病、糖尿病神经病和糖尿病视网膜病变。此外，本发明还涉及使用式I的化合物，特别是作为药物的活性成分以及包含它们的制药组合物。
• 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
  申请人：SANOFI

  公开号：EP2567959A1

  公开（公告）日：2013-03-13

  The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula, in which R1, R2, R3, R4 and R5 are defined as indicated below. The compounds of the formula are kinase C (PKC) inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式中的吡唑并[3,4-b]吡啶化合物、 其中 R1、R2、R3、R4 和 R5 的定义如下所示。式中化合物是激酶 C (PKC) 抑制剂，可用于治疗与糖尿病和糖尿病并发症有关的疾病，例如糖尿病肾病、糖尿病神经病变和糖尿病视网膜病变。本发明还涉及式化合物的用途，特别是作为药物的活性成分，以及包含它们的药物组合物。
• 6-(4-HYDROXY-PHENYL)-3-STYRYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS
  申请人：SANOFI

  公开号：EP2567959B1

  公开（公告）日：2014-04-16
• US8846712B2
  申请人：——

  公开号：US8846712B2

  公开（公告）日：2014-09-30